Many beneficiaries of the new Medicare drug program reportedly are encountering restrictions on the drugs available to them as insurers push enrollees toward generic or less costly brand-name drugs. The top Medicare official said the government is watching the program but has not yet seen a need to intervene.

Related Summaries